Axogen, Inc. (FRA:LT3)
Germany · Delayed Price · Currency is EUR | Market Cap | 1.99B +178.8% |
| Revenue (ttm) | 219.85M +23.6% |
| Net Income | -29.36M |
| EPS | -0.60 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | 61.10 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 10 |
| Open | 31.86 |
| Previous Close | 31.55 |
| Day's Range | 31.86 - 31.86 |
| 52-Week Range | 15.00 - 44.33 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 28, 2026 |
About Axogen
Axogen, Inc., together with its subsidiaries, engages in the development and commercialization of the technologies used for peripheral nerve regeneration and repair worldwide. The company offers Avance Nerve Graft, a processed nerve allograft intended for the surgical repair of peripheral nerve discontinuities; Axoguard Nerve Connector, a coaptation aid used to align and connect severed peripheral nerve ends in a tensionless repair; and Axoguard Nerve Protector, a product used to protect and wrap damaged peripheral nerves and reinforce reconstr... [Read more]
Financial Performance
In 2025, Axogen's revenue was $225.21 million, an increase of 20.21% compared to the previous year's $187.34 million. Losses were -$15.70 million, 57.6% more than in 2024.
Financial numbers in USD Financial StatementsNews
AxoGen price target lowered to $50 from $55 at Barclays
Barclays lowered the firm’s price target on AxoGen (AXGN) to $50 from $55 and keeps an Overweight rating on the shares. The firm says its scenario analysis indicates the BioCircuit…
Axogen, Inc. to Report Third Quarter 2026 Financial Results on October 28, 2026
ALACHUA, Fla. and TAMPA, Fla.
AxoGen initiated with a Buy at BofA
BofA initiated coverage of AxoGen (AXGN) with a Buy rating and $52 price target As the “only company” with a full nerve repair suite and differentiated allograft solution, the firm…
AxoGen initiated with an Overweight at Barclays
Barclays initiated coverage of AxoGen (AXGN) with an Overweight rating and $55 price target The firm rolled out coverage of the medical suppliers and devices group with a Positive rating.
AxoGen should be bought on weakness, says Lake Street
Lake Street expects consistent execution from core Axogen (AXGN) to be complemented by Nerve Tape and recent new commercial wins and thinks consistent execution and outperformance can support multiple...
Axogen Completes Acquisition of BioCircuit Technologies, Adding NerveTape™, the First FDA Cleared Device for Sutureless Peripheral Nerve Repair
ALACHUA, Fla. and TAMPA, Fla.
AxoGen price target lowered to $53 from $60 at Truist
Truist analyst Ravi Misra lowered the firm’s price target on AxoGen (AXGN) to $53 from $60 and keeps a Buy rating on the shares. The firm is adjusting its model…
AxoGen price target raised to $53 from $48 at Raymond James
Raymond James raised the firm’s price target on AxoGen (AXGN) to $53 from $48 and keeps an Outperform rating on the shares. AxoGen’s growth profile remains compelling, led by its…
Axogen Transcript: M&A announcement
The acquisition of BioCircuit for $200 million brings NerveTape, a high-growth, FDA-approved nerve repair device, into the portfolio. The deal is expected to be accretive to revenue and EBITDA by 2027, with minimal integration risk and significant market expansion potential.
Axogen Press release: M&A announcement
Axogen issued a press release on September 10, 2026, disclosing material business information to investors.
Axogen Slides: M&A announcement
Axogen has posted slides in relation to its latest quarterly earnings report, which was published on September 10, 2026.
AxoGen 4.91M share Secondary priced at $42.50
BofA Securities, Jefferies and Wells Fargo Securities are acting as lead book-running managers for the proposed offering. Mizuho Securities USA is also acting as a bookrunner for the proposed offering...
AxoGen to acquire BioCircuit Technologies
Axogen (AXGN) has entered into a definitive agreement to acquire BioCircuit Technologies, a privately held medical device company and developer of NerveTape, the first FDA-approved device for suturele...
Axogen Announces Pricing of $208.7 Million Public Offering of Common Stock
ALACHUA, Fla. and TAMPA, Fla., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (“Axogen” or the “Company”) (Nasdaq: AXGN), a global leader in developing and marketing innovative surgical solutions for...
Axogen Enters into Definitive Agreement to Acquire BioCircuit Technologies
Acquisition adds NerveTape™, the 1st FDA-approved device for sutureless peripheral nerve repair, broadening Axogen's addressable market within its focus markets
Axogen, Inc. to Participate in the 24th Annual Morgan Stanley Global Healthcare Conference
ALACHUA, Fla. and TAMPA, Fla.
AxoGen initiated with a Buy at Truist
Truist initiated coverage of AxoGen (AXGN) with a Buy rating and $60 price target The firm views AxoGen as a “unique high-growth” peripheral nerve repair company, marketing the first and…
AxoGen price target raised to $55 from $50 at Jefferies
Jefferies analyst Michael Sarcone raised the firm’s price target on AxoGen (AXGN) to $55 from $50 and keeps a Buy rating on the shares after a “beat & raise” in…
AxoGen price target raised to $55 from $50 at Canaccord
Canaccord raised the firm’s price target on AxoGen (AXGN) to $55 from $50 and keeps a Buy rating on the shares. The firm said they posted a strong quarter against…
AxoGen price target raised to $53 from $50 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on AxoGen (AXGN) to $53 from $50 and keeps a Buy rating on the shares. The company reported “robust” sales growth in Q2,…
AxoGen price target raised to $55 from $50 at Citizens
Citizens analyst David Turkaly raised the firm’s price target on AxoGen (AXGN) to $55 from $50 and keeps an Outperform rating on the shares. AxoGen continues to deliver standout growth,…
AxoGen price target raised to $55 from $50 at Jefferies
Jefferies raised the firm’s price target on AxoGen (AXGN) to $55 from $50 and keeps a Buy rating on the shares. Q2 sales were better than consensus, and the company…
Axogen Earnings Call Transcript: Q2 2026
Q2 2026 saw 23.1% revenue growth, led by accelerating Breast market adoption and strong Avance demand. Updated guidance calls for at least 24% revenue growth and 73% gross margin for the year, with robust sales force productivity and continued investment in innovation and evidence generation.
Axogen Slides: Q2 2026
Axogen has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 29, 2026.
Axogen Quarterly report: Q2 2026
Axogen has published its Q2 2026 quarterly earnings report on July 29, 2026.